— On an FX-adjusted basis, revenues grew by 6%, primarily driven by growth in the US Pharmaceutical and Specialty Solutions segment, largely due to branded pharmaceutical price increases and higher volumes from retail national account customers.
— Revenues from the US Pharma segment increased by 6% driven by branded pharmaceutical price increases and increased volumes from retail national account customers.
— European Pharmaceutical Solutions segment revenue remained flat on a reported basis and up 3% on an FX-adjusted basis, driven primarily by growth in the pharmaceutical distribution business.
— Revenue from the Medical-Surgical Solutions segment increased by 6% driven by higher pharmaceutical volumes and an early start to the influenza season.
— The company reaffirmed fiscal 2020 adjusted EPS guidance range of $14.60–14.80. The consensus estimates EPS of $14.70 for the full year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.